Retatrutide's Phase 2 trial data (Jastreboff et al., NEJM 2023) identified a side-effect profile broadly consistent with other incretin-based therapies: Gastrointestinal : Nausea, vomiting, diarrhoea, and constipation were the most commonly reported adverse effects, particularly during dose escalation
Additional work has proposed a possible connection to lipase activity, which could influence fat storage dynamics
For wellness optimizers experimenting with longevity stacks, mitochondrial support, or inflammation balancing regimens, Healthletic BPC-157 represents a practical tool
Stress and long work hours made recovery challenging
It also ramps up your metabolism, which allows you to burn more calories and lose weight
Start Your Medical Weight Loss Journey Free 15-minute discovery call with our Houston team